Lymphoma
Identify Distinct Signatures of Lymphoma Subgroup
Lymphomas are a broad variety of clonal neoplasms of the lymphatic system, and a vast majority of lymphoma cases are derived from B-cells. Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell lymphoma worldwide and is divided into sub-groups based on the cell of origin (COO). Determine the COO for DLBCL using HTG EdgeSeq Reveal signatures.
Utilize Differential Gene Expression to Identify Lymphoma Subtypes
Elucidate Genes Involved in Transcriptional Response to Disease State or Drug Therapy
Determine Cell of Origin Sub-Type Using HTG EdgeSeq Reveal DLBCL COO Signature
Utilize Differential Gene Expression to Identify Lymphoma Subtypes
Gene expression profiles are commonly used to identify lymphoma subgroups using published gene signatures or identifying previously undescribed biomarkers to differentiate lymphoma subtypes. Accurately measure expression of genes commonly associated with indolent and aggressive lymphomas with the HTG EdgeSeq Pan B-cell Lymphoma panel.
Elucidate Genes Involved In Transcriptional Response to Disease State or Drug Therapy
In addition to genes associated with lymphoma subtype, the HTG EdgeSeq Pan B-cell Lymphoma assay can also help elucidate genes involved in the transcription response of that disease state or drug therapy, allowing researchers to quickly identify biomarkers.
Determine Cell of Origin Subtype Using HTG EdgeSeq Reveal DLBCL COO Signature
Diffuse large B-cell lymphoma (DLBCL) is routinely classified by the cell of origin (COO), with germinal center B-cell (GCB) being more common and indicating better prognosis than Activated B-cell (ABC). Due to the differences in outcome to treatment response, a significant portion of research has been focused on understanding the molecular differences between these two subtypes. Learn how you can use HTG EdgeSeq Reveal DLBCL COO Signature to determine the predicted probability that a sample is an ABC of GCB subtype.
